Official and regulatory announcements from Abera Bioscience, including financial reports, clinical trial updates, and material corporate events.
Sammanfattning av delårsrapport Q3 2021. FINANSIELL ÖVERSIKT FÖRSTA TRE KVARTALEN 2021 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 769 (653) kSEK Resultatet efter finansiella poster uppgick till -6 554 (-1 758) kSEK. Resultat per aktie: -0,65 (-0,25) SEK. Soliditeten uppgick till 93 (72) %. FINANSIELL ÖVERSIKT
Proof-of-concept data for Abera Bioscience’s latest vaccine platform based on protein bodies have been published in the journal Vaccine. The article reports on the examination of several intranasal vaccine candidates against pneumococcus based on protein bodies. The results demonstrate induction of strong protection against colonization of bacteria in the nasal
Abera Bioscience AB initiates collaboration with an American university to accelerate the development of a vaccine candidate based on the company’s latest vaccine platform comprising protein bodies. Abera Bioscience AB is a biotechnology company that develops vaccine candidates based on patented vaccine platforms. The latest vaccine platform makes it possible
Abera Bioscience AB receives a grant from Vinnova, Sweden’s innovation agency, of SEK 400,000 within the call “Preparatory project for international application in health 2021”. Abera intends to attract the leading experts in the field and build a competitive consortium and project for the development of vaccines based on the
Abera Bioscience AB (“Abera” or “the Company”) continues to develop its vaccine platforms together with prominent universities. Now, a PhD thesis by Lucille F. Van Beek from our collaborator Radboud University (Nijmegen, the Netherlands) has been published focused at innovative vaccine design. One of the included chapters, which has not
As previously announced, the vaccine platform developed by Abera Bioscience AB (“Abera” or “the Company”) has been used in a collaboration between researchers at Johns Hopkins University School of Medicine (Baltimore, USA) and Vrije Universiteit (Amsterdam, the Netherlands) to produce and test a novel, nasal SARS-CoV-2 vaccine candidate. Previously published
Abera Bioscience AB (“Abera” or “the Company”) continues to improve its vaccine platform in collaboration with researchers at Vrije Universiteit Amsterdam. An article was recently published in the peer-reviewed journal Microbial Cell Factories by researchers Trang H. Phan, Coen Kuijl and Peter van Ulsen of Vrije Universiteit Amsterdam in collaboration
Abera Bioscience AB (publ) publicerar halvårsrapport 2021. FINANSIELL ÖVERSIKT FÖRSTA HALVÅRET 2021 Nettoomsättningen uppgick till 0 (0) TSEK. Övriga rörelseintäkter uppgick till 463 (475) TSEK. Resultatet efter finansiella poster uppgick till -4 619 (-1 301) TSEK. Resultat per aktie: -0,47 (-0,19) SEK. Soliditeten uppgick till 90 (79) %. FINANSIELL
Abera Bioscience AB has received so-called Notice of Allowance of the company’s patent application “ Fusion polypeptides comprising one or more inclusion body tags, methods and uses ” by the US Patent Office (USPTO). The patent forms the basis of a new vaccine platform that the company has developed in
The vaccine platform developed by Abera Bioscience AB (“Abera” or “the Company”) has been used in a collaboration between researchers at Johns Hopkins University School of Medicine (Baltimore, USA) and Vrije Universiteit (Amsterdam, the Netherlands) to produce and test a novel SARS-CoV-2 vaccine candidate. Now the results from a study